Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2007 2
2011 2
2012 7
2013 8
2014 6
2015 9
2016 7
2017 11
2018 4
2019 6
2020 14
2021 17
2022 17
2023 13
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Matoba Y, Zarrella DT, Pooladanda V, Azimi Mohammadabadi M, Kim E, Kumar S, Xu M, Qin X, Ray LJ, Devins KM, Kumar R, Kononenko A, Eisenhauer E, Veillard IE, Yamagami W, Hill SJ, Sarosiek KA, Yeku OO, Spriggs DR, Rueda BR. Matoba Y, et al. Among authors: yamagami w. Br J Cancer. 2024 May;130(9):1463-1476. doi: 10.1038/s41416-024-02621-x. Epub 2024 Mar 4. Br J Cancer. 2024. PMID: 38438589 Free PMC article.
Impact of COVID-19 on gynecological cancer incidence: a large cohort study in Japan.
Komatsu H, Ikeda Y, Kawana K, Nagase S, Yoshino K, Yamagami W, Tokunaga H, Kato K, Kimura T, Aoki D, Obstetrics TCOGOOTJSO, Gynecology. Komatsu H, et al. Among authors: yamagami w. Int J Clin Oncol. 2024 Jan;29(1):72-77. doi: 10.1007/s10147-023-02431-w. Epub 2023 Dec 6. Int J Clin Oncol. 2024. PMID: 38055097
BRCA1/2 reversion mutations in a pan-cancer cohort.
Nakamura K, Hayashi H, Kawano R, Ishikawa M, Aimono E, Mizuno T, Kuroda H, Kojima Y, Niikura N, Kawanishi A, Takeshita K, Suzuki S, Ueno S, Okuwaki K, Sasaki J, Yamaguchi M, Masuda K, Chiyoda T, Yamagami W, Okada C, Nohara S, Tanishima S, Nishihara H. Nakamura K, et al. Among authors: yamagami w. Cancer Sci. 2024 Feb;115(2):635-647. doi: 10.1111/cas.16033. Epub 2023 Dec 1. Cancer Sci. 2024. PMID: 38041241 Free PMC article.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology: Annual Patient Report for 2020 and Annual Treatment Report for 2015.
Yoshino K, Kurita T, Takahashi F, Nagase S; Board members of the 2022 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Yoshino K, et al. J Obstet Gynaecol Res. 2023 Nov;49(11):2584-2592. doi: 10.1111/jog.15767. Epub 2023 Aug 21. J Obstet Gynaecol Res. 2023. PMID: 37602964
108 results